



Innovating for
affordable healthcare

Shilpa Medicare Limited

Manufacturers and Exporters of Bulk Drugs

Shilpa House # 12-6-214/A-1, Hyderabad Road,
RAICHUR - 584 135, Karnataka, India.

Phone : +91-8532-238704, Fax : +91-8532-238876

E-mail : info@vbshilpa.com Website : <http://www.vbshilpa.com>

CIN No. L85110KA1987PLC008739

Dated: 18 January, 2019

Corporate Relationship Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai-400 001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
MUMBAI-400 051

Dear Sir/Madam,

**Sub: Intimation U/R 30 of the SEBI(LODR) Regulations- Reg.
Ref: Stock Code: NSE: SHILPAMED/BSE-530549**

This is to inform you that the Company has received U.S Food and Drug Administration approval for its ANDA, Imatinib Mesylate Tablets, 100 mg and 400 mg on 17.01.2019.

Imatinib Mesylate Tablets is a generic equivalent of the reference listed drug (RLD); gleevec Tablets, 100 mg and 400 mg used in the treatment of leukemia as recommended in the label approved by FDA.

According to IQVIA MAT Q2 2018 data, the US market for Imatinib Mesylate Tablets, 100 mg and 400 mg is approximately US\$ 885 Million.

This is for your information and doing the needful.

With Regards,

For **SHILPA MEDICARE LIMITED**

VISHNUKANTH C BHUTADA
Managing Director

